不同剂量BPI-1095对大鼠局灶性脑缺血损伤的保护研究  

Neuroprotective Effects of different doses of BPI-1095 in Focal Cerebral Ischemia Rats

作　　者：王春雪[1] 毛淑静[2] 万虹[3] 历俊华[3] 翟晶[3] 刘丽萍[1] 王拥军[1] 

机构地区：[1]首都医科大学附属北京天坛医院神经内科,北京市100050 [2]北京护士学校药理组,北京市101149 [3]北京市神经外科研究所,北京市100050

出　　处：《中国康复理论与实践》2007年第1期32-34,共3页Chinese Journal of Rehabilitation Theory and Practice

基　　金：北京市优秀人才基金资助项目(20061d0300416)

摘　　要：目的 探讨BPI-1095对大鼠局灶性脑缺血损伤的保护作用。方法 90只SD大鼠被随机分成6组：BPI-1095大剂量组（240mg／kg）、BPI-1095中剂量组（80mg／kg）、BPI-1095小剂量组（27mg／kg）、阿司匹林组（80mg／kg）、安慰剂组、假手术组，每组15只。于线栓法复制永久性大脑中动脉闭塞缺血模型术后10min，动物分别以灌胃的方式给予不同剂量的观察药物及对照药物。于给药后4h、24h采用动物行为学量表对缺血动物的神经功能进行评价。24h评分完成后，在造模成功且存活的各组动物中，每组随机取7或8只（使每组各剩余5只）用氯化三苯四唑（TTC）染色，利用计算机图像分析系统测定大脑半球梗死面积百分数。结果 大剂量及中剂量BPI-1095可以改善缺血大鼠神经功能障碍（P〈0．05）；大、中剂量治疗组梗死面积百分数小于安慰剂组（P〈0．05）。结论 80～240mg／kg BPI-1095可以改善局灶性脑缺血大鼠的神经功能，缩小梗死体积。Objective To investigate the neuroprotective effects of different doses of BPI-1095 on infarct volume and neurological outcome in middle cerebral artery oeelusion（MCAO） rats. Methods Cerebral isehemia model was induced with MCAO in adult male SD rats. 10 minutes after surgery, rats were randomly subjected into six groups with 15 rats in each group. Each rat has been given different dosage tested medication and was sacrificed 24 h after treatment. Neurological functional behaviour tests were performed 4 h and 24 h after treatment. After the final behaviour test, 7 or 8 rats （remain 5 rats for brain tissue stain） were randomly picked up from each group. Their infarction volume was measured with image analysis system after 2% triphenyl-tetrazolium chloride （TTC） stain. Results High dose （240 mg/kg） and moderate dose （80 mg/kg） of BPI-1095 were able to improve the neurological deficit in MCAO rats （P〈0.05, vs vehicle-treated group）, as well as they decrease the infraeted volume （P〈0.05, vs the vehlcle-treated group ） 24 h after ischemia. Conclusion 80-240 mg/kg BPI-1095 is able to improve neurological deficit effectively and reduce infarct volume significantly.

关 键 词：大脑中动脉闭塞(MCAO) 局灶性脑缺血 动物行为学 大鼠 

分 类 号：R743.3[医药卫生—神经病学与精神病学]